(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of 0.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.39%.
Puma Biotechnology's revenue in 2024 is $235,637,000.On average, 2 Wall Street analysts forecast PBYI's revenue for 2024 to be $10,615,940,180, with the lowest PBYI revenue forecast at $10,615,217,072, and the highest PBYI revenue forecast at $10,616,663,287. On average, 3 Wall Street analysts forecast PBYI's revenue for 2025 to be $11,537,227,253, with the lowest PBYI revenue forecast at $11,333,503,786, and the highest PBYI revenue forecast at $11,762,547,528.
In 2026, PBYI is forecast to generate $12,039,497,674 in revenue, with the lowest revenue forecast at $12,037,328,351 and the highest revenue forecast at $12,041,666,996.